Clinical Trial Update: Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial results evaluate the combination of atezolizumab and CYT107 in participants with locally advanced, inoperable, or metastatic urothelial carcinoma …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Renal Pelvis Cancer
• Ureteral Cancer
• Urethral Cancer

Drugs mentioned

• CYT107 (CYT107)
• Tecentriq (atezolizumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Bladder Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2024-07-03